Various clinical presentations of uveitis associated with durvalumab treatment

1Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 2019; 394: 1929-39. doi: 10.1016/S0140-6736(19)32222-6Paz-Ares L Dvorkin M Chen Y Reinmuth N Hotta K Trukhin D et al Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial Lancet 2019 394 1929 39 10.1016/S0140-6736(19)32222-631590988Open DOISearch in Google Scholar

2European Medicines Agency. Imfinzi, INN-durvalumab. 2020. [cited 30 Nov 2020]. Available at: https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdfEuropean Medicines Agency Imfinzi, INN-durvalumab 2020 [cited 30 Nov 2020]. Available at https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdfSearch in Google Scholar

3Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, et al. Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci Rep 2017; 7: 5532. doi: 10.1038/s41598-017-06002-8Lee HT Lee JY Lim H Lee SH Moon YJ Pyo HJ et al Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab Sci Rep 2017 7 5532 10.1038/s41598-017-06002-8551410328717238Open DOISearch in Google Scholar

4Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64. doi: 10.1038/nrc3239Pardoll DM The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 2012 12 252 64 10.1038/nrc3239485602322437870Open DOISearch in Google Scholar

5Sun MM, Levinson RD, Filipowicz A, Anesi S, Kaplan HJ, Wang W, et al. Uveitis in patients treated with CTLA-4 and PD-1 checkpoint blockade inhibition. Ocul Immunol Inflamm 2020; 28: 217-27. doi: 10.1080/09273948.2019.1577978Sun MM Levinson RD Filipowicz A Anesi S Kaplan HJ Wang W et al Uveitis in patients treated with CTLA-4 and PD-1 checkpoint blockade inhibition Ocul Immunol Inflamm 2020 28 217 27 10.1080/09273948.2019.1577978683281130821569Open DOISearch in Google Scholar

6Dow ER, Yung M, Tsui E. Immune checkpoint inhibitor-associated uveitis: review of treatments and outcomes. Ocul Immunol Inflamm 2021; 29: 20311. doi: 10.1080/09273948.2020.1781902Dow ER Yung M Tsui E Immune checkpoint inhibitor-associated uveitis: review of treatments and outcomes Ocul Immunol Inflamm 2021 29 20311 10.1080/09273948.2020.178190232815757Open DOISearch in Google Scholar

7Parikh RA, Chaon BC, Berkenstock MK. Ocular complications of checkpoint inhibitors and immunotherapeutic agents: a case series. Ocul Immunol Inflamm 2021; 29: 1585-90. doi: 10.1080/09273948.2020.17660828Parikh RA Chaon BC Berkenstock MK Ocular complications of checkpoint inhibitors and immunotherapeutic agents: a case series Ocul Immunol Inflamm 2021 29 1585 90 10.1080/09273948.2020.17660828Open DOISearch in Google Scholar

8Andrade AR, Moll-Udina A, Martin R, Cilveti E, Subirà O, Disfetano L, et al. Retinal vasculitis secondary to durvalumab. Case Rep Ophthalmol 2020; 11: 161-6. doi: 10.1159/000507609Andrade AR Moll-Udina A Martin R Cilveti E Subirà O Disfetano L et al Retinal vasculitis secondary to durvalumab Case Rep Ophthalmol 2020 11 161 6 10.1159/000507609725038132508622Open DOISearch in Google Scholar

9Hahn L, Pepple KL. Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma. J Ophthal Inflamm Infect 2016; 6: 14. doi: 10.1186/s12348-016-0082-3Hahn L Pepple KL Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma J Ophthal Inflamm Infect 2016 6 14 10.1186/s12348-016-0082-3486488527165193Open DOISearch in Google Scholar

10Aaberg MT, Aaberg TM. Pembrolizumab administration associated with posterior uveitis. Retin Cases Brief Rep 2017; 11: 348-51. doi: 10.1097/ICB.0000000000000368Aaberg MT Aaberg TM Pembrolizumab administration associated with posterior uveitis Retin Cases Brief Rep 2017 11 348 51 10.1097/ICB.000000000000036827490976Open DOISearch in Google Scholar

11Wang W, Lam WC, Chen L. Recurrent grade 4 panuveitis with serous retinal detachment related to nivolumab treatment in a patient with metastatic renal cell carcinoma. Cancer Immunol Immunother 2019; 68: 85-95. doi: 10.1007/s00262-018-2260-7Wang W Lam WC Chen L Recurrent grade 4 panuveitis with serous retinal detachment related to nivolumab treatment in a patient with metastatic renal cell carcinoma Cancer Immunol Immunother 2019 68 85 95 10.1007/s00262-018-2260-730311026Open DOISearch in Google Scholar

12Reid G, Lorigan P, Heimann H, Hovan M. et al. Management of chronic hypotony following bilateral uveitis in a patient treated with pembrolizumab for cutaneous metastatic melanoma. Ocul Immunol Inflamm 2019; 27: 1012–15. doi: 10.1080/09273948.2018.1459733Reid G Lorigan P Heimann H Hovan M. et al Management of chronic hypotony following bilateral uveitis in a patient treated with pembrolizumab for cutaneous metastatic melanoma Ocul Immunol Inflamm 2019 27 1012 15 10.1080/09273948.2018.145973329672247Open DOISearch in Google Scholar

13Navarro-Perea C, Garcia-Gonzalez J, Perez-Blazquez E. Case report: bilateral uveitis and papillitis secondary to treatment with pembrolizumab. Indian J Ophthalmol 2019; 67: 2075-7. doi: 10.4103/ijo.IJO_1161_19Navarro-Perea C Garcia-Gonzalez J Perez-Blazquez E Case report: bilateral uveitis and papillitis secondary to treatment with pembrolizumab Indian J Ophthalmol 2019 67 2075 7 10.4103/ijo.IJO_1161_19689654431755465Open DOISearch in Google Scholar

14Kim YJ, Lee JS, Lee J, Lee SC, Kim TI, Byeon SH, et al. Factors associated with ocular adverse event after immune checkpoint inhibitor treatment. Cancer Immunol Immunother 2020; 69: 2241-52. doi: 10.1007/s00262-020-02635-3Kim YJ Lee JS Lee J Lee SC Kim TI Byeon SH et al Factors associated with ocular adverse event after immune checkpoint inhibitor treatment Cancer Immunol Immunother 2020 69 2241 52 10.1007/s00262-020-02635-332556494Open DOISearch in Google Scholar

15Kikuchi R, Kawagoe T, Hotta K. Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report. BMC Ophthalmol 2020; 20: 252. doi: 10.1186/s12886-020-01519-5Kikuchi R Kawagoe T Hotta K Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report BMC Ophthalmol 2020 20 252 10.1186/s12886-020-01519-5731317032580711Open DOISearch in Google Scholar

16Young L, Finnigan S, Streicher H, Chen HX, Murray J, Sen HN, et al. Ocular adverse events in PD-1 and PD-L1 inhibitors. J Immunother Cancer 2021; 9: e002119. doi: 10.1136/jitc-2020-002119Young L Finnigan S Streicher H Chen HX Murray J Sen HN et al Ocular adverse events in PD-1 and PD-L1 inhibitors J Immunother Cancer 2021 9 e002119 10.1136/jitc-2020-002119825867034226280Open DOISearch in Google Scholar

17Carrera W, Baartman BJ, Kosmorsky G. A case report of drug-induced myopathy involving extraocular muscles after combination therapy with tremelimumab and durvalumab for non-small cell lung cancer. Neuro-Ophthalmol 2017; 41: 140-3. doi: 10.1080/01658107.2017.1291686Carrera W Baartman BJ Kosmorsky G A case report of drug-induced myopathy involving extraocular muscles after combination therapy with tremelimumab and durvalumab for non-small cell lung cancer Neuro-Ophthalmol 2017 41 140 3 10.1080/01658107.2017.1291686541708328512504Open DOISearch in Google Scholar

18Noble CW, Gangaputra SS, Thompson IA, Yuan A, Apolo AB, Lee JM, et al. Ocular adverse events following use of immune checkpoint inhibitors for metastatic malignancies. Ocul Immunol Inflamm 2020; 28: 854-9. doi: 10.1080/09273948.2019.1583347Noble CW Gangaputra SS Thompson IA Yuan A Apolo AB Lee JM et al Ocular adverse events following use of immune checkpoint inhibitors for metastatic malignancies Ocul Immunol Inflamm 2020 28 854 9 10.1080/09273948.2019.1583347813084331013173Open DOISearch in Google Scholar

19Sabini E, Sframeli A, Marinò M. A case of drug-induced Graves’ orbitopathy after combination therapy with tremelimumab and durvalumab. J Endocrinol Invest 2018; 41: 877-8. doi: 10.1007/s40618-018-0906-0Sabini E Sframeli A Marinò M A case of drug-induced Graves’ orbitopathy after combination therapy with tremelimumab and durvalumab J Endocrinol Invest 2018 41 877 8 10.1007/s40618-018-0906-029804271Open DOISearch in Google Scholar

20Yang W, Li H, Chen PW, Chen HX, Murray J, Sen HN, et al. PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation. Invest Ophthalmol Vis Sci 2009; 50: 273-80. doi: 10.1167/iovs.08-2397Yang W Li H Chen PW Chen HX Murray J Sen HN et al PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation Invest Ophthalmol Vis Sci 2009 50 273 80 10.1167/iovs.08-239718791172Open DOISearch in Google Scholar

21Francis JH, Berry D, Abramson DH, Barker CA, Bergstrom C, Demirci H, et al. Intravitreous cutaneous metastatic melanoma in the era of checkpoint inhibition. Ophthalmology 2020; 127: 240-8. doi: 10.1016/j.ophtha.2019.09.018Francis JH Berry D Abramson DH Barker CA Bergstrom C Demirci H et al Intravitreous cutaneous metastatic melanoma in the era of checkpoint inhibition Ophthalmology 2020 127 240 8 10.1016/j.ophtha.2019.09.018700353731708274Open DOISearch in Google Scholar

22Sun MM, Seleme N, Chen JJ, et al. Neuro-ophthalmic complications in patients treated with CTLA-4 and PD-1/PD-L1 checkpoint blockade. J Neuroophthalmol 2021; 41: 519-30. doi; 10.1097/WNO.0000000000001148Sun MM Seleme N Chen JJ et al Neuro-ophthalmic complications in patients treated with CTLA-4 and PD-1/PD-L1 checkpoint blockade J Neuroophthalmol 2021 41 519 30 10.1097/WNO.000000000000114810.1097/WNO.000000000000114833136674Search in Google Scholar

23Gordon L, Dinkin M. Paraneoplastic syndromes in neuro-ophthalmology. Continuum (Minneap Minn) 2019; 25: 1401-21. doi: 10.1212/CON.0000000000000788.Gordon L Dinkin M Paraneoplastic syndromes in neuro-ophthalmology Continuum (Minneap Minn) 2019 25 1401 21 10.1212/CON.000000000000078831584543Open DOISearch in Google Scholar

24Xu Q, Du W, Zhou H, Zhang X, Liu H, Song H, et al. Distinct clinical characteristics of paraneoplastic optic neuropathy. Br J Ophthalmol 2019; 103: 797-801. doi: 10.1136/bjophthalmol-2018-312046Xu Q Du W Zhou H Zhang X Liu H Song H et al Distinct clinical characteristics of paraneoplastic optic neuropathy Br J Ophthalmol 2019 103 797 801 10.1136/bjophthalmol-2018-31204630021813Open DOISearch in Google Scholar

25Cross SA, Salomao DR, Parisi JE, Kryzer TJ, Bradley EA, Mines JA, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 2003; 54: 38-50. doi: 10.1002/ana.10587Cross SA Salomao DR Parisi JE Kryzer TJ Bradley EA Mines JA et al Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG Ann Neurol 2003 54 38 50 10.1002/ana.1058712838519Open DOISearch in Google Scholar

26Adamus G, Champaigne R, Yang S. Occurrence of major anti-retinal autoantibodies associated with paraneoplastic autoimmune retinopathy. Clin Immunol 2020; 210: 108317. doi: 10.1016/j.clim.2019.108317Adamus G Champaigne R Yang S Occurrence of major anti-retinal autoantibodies associated with paraneoplastic autoimmune retinopathy Clin Immunol 2020 210 108317 10.1016/j.clim.2019.108317698936731770612Open DOISearch in Google Scholar

27Yagyu K, Ueda T, Miyamoto A, Uenishi R, Matsushita H, Tanaka T. Cancerassociated retinopathy with neuroendocrine combined large-cell lung carcinoma and adenocarcinoma. Intern Med 2019; 58: 3289-94. doi: 10.2169/internalmedicine.2313-18Yagyu K Ueda T Miyamoto A Uenishi R Matsushita H Tanaka T Cancerassociated retinopathy with neuroendocrine combined large-cell lung carcinoma and adenocarcinoma Intern Med 2019 58 3289 94 10.2169/internalmedicine.2313-18691173831327819Open DOISearch in Google Scholar

28Hoogewoud F, Butori P, Blanche P, Brézin AP. Cancer-associated retinopathy preceding the diagnosis of cancer. BMC Ophthalmol 2018; 18: 285. doi: 10.1186/s12886-018-0948-2Hoogewoud F Butori P Blanche P Brézin AP Cancer-associated retinopathy preceding the diagnosis of cancer BMC Ophthalmol 2018 18 285 10.1186/s12886-018-0948-2621563530390655Open DOISearch in Google Scholar

29Makiyama Y, Kikuchi T, Otani A, Oishi A, Guo C, Nakagawa S, et al. Clinical and immunological characterization of paraneoplastic retinopathy. Invest Ophthalmol Vis Sci 2013; 54: 5424-31. doi: 10.1167/iovs.13-11868Makiyama Y Kikuchi T Otani A Oishi A Guo C Nakagawa S et al Clinical and immunological characterization of paraneoplastic retinopathy Invest Ophthalmol Vis Sci 2013 54 5424 31 10.1167/iovs.13-1186823860756Open DOISearch in Google Scholar

30Pepple KL, Cusick M, Jaffe GJ, Mruthyunjaya P. SD-OCT and autofluorescence characteristics of autoimmune retinopathy. Br J ophthalmol 2013; 97: 13944. doi: 10.1136/bjophthalmol-2012-302524Pepple KL Cusick M Jaffe GJ Mruthyunjaya P SD-OCT and autofluorescence characteristics of autoimmune retinopathy Br J ophthalmol 2013 97 13944 10.1136/bjophthalmol-2012-30252423221966Open DOISearch in Google Scholar

31Lee KM, Woo SJ, Hwang JM. Factors associated with visual field defects of optic disc. PLoS One 2018; 13: e0196001. doi: 10.1371/journal.pone.0196001Lee KM Woo SJ Hwang JM Factors associated with visual field defects of optic disc PLoS One 2018 13 e0196001 10.1371/journal.pone.0196001592740229708976Open DOISearch in Google Scholar

32Casado A, Rebolleda G, Guerrero L, Leal M, Contreras I, Oblanca N, et al. Measurement of retinal nerve fiber layer and macular ganglion cell–inner plexiform layer with spectral-domain optical coherence tomography in patients with optic nerve head drusen. Graefes Arch Clin Exp Ophthalmol 2014; 252: 1653-60. doi: 10.1007/s00417-014-2773-5Casado A Rebolleda G Guerrero L Leal M Contreras I Oblanca N et al Measurement of retinal nerve fiber layer and macular ganglion cell–inner plexiform layer with spectral-domain optical coherence tomography in patients with optic nerve head drusen Graefes Arch Clin Exp Ophthalmol 2014 252 1653 60 10.1007/s00417-014-2773-525128962Open DOISearch in Google Scholar

33Coscas G, De Benedetto U, Coscas F, Li Calzi CI, Vismara S, Roudot-Thoraval F, et al. Hyperreflective dots: a new spectral-domain optical coherence tomography entity for follow-up and prognosis in exudative age-related macular degeneration. Ophthalmologica 2013; 229: 32-7. doi: 10.1159/000342159Coscas G De Benedetto U Coscas F Li Calzi CI Vismara S Roudot-Thoraval F et al Hyperreflective dots: a new spectral-domain optical coherence tomography entity for follow-up and prognosis in exudative age-related macular degeneration Ophthalmologica 2013 229 32 7 10.1159/00034215923006969Open DOISearch in Google Scholar